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1. Introduction 
1.1 Primary biliary cirrhosis 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by immune-
mediated, chronic nonsuppurative cholangitis that affects interlobular and septal bile ducts 
(Kaplan & Gershwin, 2005). PBC is a rare disease, with prevalence ranging from 28 to 402 per 
million depending on geographical location (Table 1). PBC predominantly affects middle aged 
women, and is exceedingly rare in males (James et al., 1999). Familial clustering of PBC cases 
has been observed, which predominantly affects female family members. Several reports 
indicate that the prevalence and incidence of PBC is increasing globally (James et al., 1999). 
Concomitant autoimmune diseases are often found in patients with PBC (Kaplan & Gershwin, 
2005). The serological hallmark of PBC is the presence of high-titer serum antimitochondrial 
autoantibodies (AMA), which are present in 90–95% of patients with PBC (Bogdanos et al., 
2003; Bogdanos et al., 2008; Bogdanos & Komorowski, 2011; Kaplan & Gershwin, 2005). The 
presence of AMA in asymptomatic patients is considered predictive of eventual disease 
development (Metcalf et al., 1996). These autoantibodies are specific to the lipoylated domains 
within components of the 2-oxoacid dehydrogenase family of enzymes, particularly the E2 
component of the pyruvate dehydrogenase complex, located within the inner mitochondrial 
membrane (Bogdanos et al., 2003; Bogdanos et al., 2008; Bogdanos & Komorowski, 2011, 
Kaplan & Gershwin, 2005). Indirect immunofluorescence using rodent liver, kidney and 
stomach sections as substrate are the most widely used screening assays for AMA in the 
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routine setting (EASL 2009). Other techniques including immunoblotting and ELISA have a 
higher sensitivity, and the use of cloned mitochondrial antigens and bead assay testing 
systems allow for the identification of AMA in the sera of patients previously defined as AMA 
negative. In addition to AMA, PBC specific anti-nuclear autoantibodies (ANA) are also 
characteristic of PBC in approximately 30% of patients presenting with multiple nuclear dot 
(antibodies against Sp100) or nuclear membrane staining patterns (antibodies against gp210) 
(Bogdanos et al., 2008; Bogdanos & Komorowski 2011; Courvalin & Worman, 1997), which 
preferentially are identified using HEp-2 cells as substrate . The multiple nuclear dot pattern 
specific for PBC needs not to be confused with the nuclear dot pattern of anticentromere 
antibodies (ACA). The autoimmune pathogenesis of PBC is supported by a plethora of 
experimental and clinical data, such as the presence of autoreactive T cells in PBC patients, and 
serum autoantibodies characteristic of the disease (Bogdanos et al., 2003; Bogdanos et al., 2010; 
Bogdanos & Vergani, 2009; Shimoda et al., 1995). 
The aetiology of PBC is unknown, however the current view is that both genetic 
susceptibility, and environmental factors are involved together, although these need further 
characterization. A number of chemicals and infectious agents have been proposed to 
induce the disease in genetically predisposed individuals (Bogdanos et al., 2010; Bogdanos 
& Vergani, 2009; Bogdanos et al., 2004a; Bogdanos et al., 2004b; Gershwin & Mackay, 2008; 
Smyk et al., 2011; Vergani et al., 2004). The presentation of PBC may include symptoms such 
as pruritus (the most specific symptom of PBC) and fatigue (the most common non-specific 
symptom), and/or jaundice (Kaplan & Gershwin, 2005). More severe patients may present 
with symptoms related to portal hypertension and its complications (Kaplan & Gershwin, 
2005). However, a significant proportion of PBC patients are asymptomatic and diagnosed 
incidentally during treatment for other conditions, which are quite often other concomitant 
autoimmune conditions (Gershwin et al., 2005; Hudson et al., 2008). Currently, a definite 
diagnosis of PBC is made on a combination of abnormal serum enzymes indicating 
cholestasis (i.e. elevated alkaline phosphatase for at least six months), the presence of serum 
AMA (titre > 1:40), and characteristic liver histology with florid bile duct lesions (EASL 
2009, Kaplan & Gershwin, 2005). The presence of two of the three criteria is indicative of a 
probable PBC diagnosis, but this definition is not globally accepted. Serum AMA may 
precede disease onset by several years, and many individuals found positive for these 
autoantibodies in the absence of other criteria eventually develop PBC (Metcalf et al., 
1996). 
The progression of PBC may extend over many decades, and is highly variable among 
patients. The final stages of this progression are characterised by cirrhosis, liver failure and 
death. However, the patterns of clinical disease and natural history have changed 
significantly in the last two decades after the introduction of medical treatment with 
ursodeoxycholic acid (UDCA). When UDCA is administered in early PBC at adequate doses 
(13-15 mg/kg/day), the progression of the disease is often altered, with many patients 
having a normal life expectancy without additional therapeutic measures. 
1.2 Systemic sclerosis (SSc) 
Systemic sclerosis (SSc) is a chronic systemic connective tissue disease characterized by 
vascular and immune dysfunction. The cardinal features are sclerosis of the skin with potential 
involvement of other organs (kidney, oesophagus, heart and lung are the most frequent 
targets), but involvement of the liver is relatively rare (Kalabay et al., 2002). The available data 
indicate a prevalence of scleroderma ranging from 50 to 200 per million (Table 1), with women 
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being at much higher risk for scleroderma than men (Chifflot et al., 2008). The poorly 
understood pathogenesis of SSc is complex. Familial clustering and the high frequency of 
other autoimmune disorders in families of patients with scleroderma, is suggestive of a 
genetic involvement (Kalabay et al., 2002). In addition, infectious agents have been 
suggested as possible contributing factors to the development and progression of SSc, 
through mechanisms of molecular mimicry and immunological cross-reactivity involving 
microbial/self homologues. SSc is extremely heterogeneous in its clinical manifestations, 
pattern of organ involvement, natural history, and survival. Survival is correlated with 
internal organ involvement and is inversely related to the severity of restrictive lung 
disease. In the kidneys, injury to the medium-sized arteries can precipitate scleroderma 
renal crisis with malignant hypertension, hyper-reninemia, microangiopathic hemolytic 
anemia, and rapidly progressive renal failure. Pulmonary arterial hypertension develops in 
40% of SSc patients, and is a major SSc complication and a leading cause of death (Kalabay 
et al., 2002). Heart involvement in SSc may include cardiac fibrosis in addition to pulmonary 
hypertension. 
The autoantibody profile in SSc appears specific and is useful for confirming the diagnosis, 
the disease subset, and for monitoring disease activity (Steen, 2005).  Autoantibodies that 
characterize limited cutaneous SSc (lcSSC) include ACA, anti-Th/To, anti-U1-RNP, and 
PM/Scl. Diffuse cutaneous SSc (dcSSc) is characterized by anti-Scl 70 antibody (anti-
topoisomerase I antibody, TOPO), anti-RNA polymerase III and anti-U3-RNP. Severe lung 
disease is the hallmark of anti-TOPO positive dcSSC patients. DcSSc patients with anti-RNA 
polymerase III appear to have the most severe skin disease and the highest frequency of 
renal crisis. Patients with the nucleolar antibody anti-U3-RNP have dcSSc with multiorgan 
involvement (Steen, 2005). 
2. PBC/SSc  
2.1 Epidemiology 
The main features of PBC and SSc are shown in Table 1. PBC is the most common liver 
disorder in SSc patients (Abraham et al., 2004). One case from 1964 reports two patients with 
SSc and possible (but unconfirmed) PBC. Murray-Lyon et al reports two cases of SSc with 
PBC (Murray-Lyon et al., 1970). Despite several similar reports over the years, liver disease 
has not been considered a significant feature of scleroderma, and larger studies have 
demonstrated that liver disease was more common in the control groups. The association of 
lcSSc and PBC was first described in 1970 with two cases of PBC and limited scleroderma 
(Murray-Lyon et al., 1970). A further six cases were also reported, and several other case 
reports have found an association between lcSSc and PBC. The first case reporting an 
association of PBC and scleroderma, without features of lcSSc, was described in 1972. The 
prevalence of clinically evident PBC among patients with SSc was recently reported to be 
2.5% in a registry of 1700 SSc patients (Norman et al., 2009), and 2% in a series of 817 
patients with SSc (Assassi et al., 2009). On the other hand, the prevalence of SSc in patients 
with PBC is estimated to be around 8%. However, case reports and some series (Akimoto et 
al., 1999) reported wider range of prevalence (3-50%) of SSc, mostly lcSSc, in PBC patients. 
Large epidemiological studies on PBC note a small number of patients who also have SSc. A 
large French study found SSc in 1% of a cohort of PBC patients, although 1% of their first 
degree relatives and 1% of controls also had scleroderma (Corpechot et al., 2010). Gershwin 
and colleagues found that 2% of PBC patients and 1% of their first degree relatives had 
scleroderma, which was not found in any of the controls (Gershwin et al., 2005). First degree 
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relatives with scleroderma were more often sisters, followed by daughters of PBC patients, 
in keeping with the high female predominance (Gershwin et al., 2005; Parikh-Patel et al., 
2001). Twin studies in both conditions are scarce. One twin study for SSc found a 
concordance of 4.2% among monozygotic (MZ) twins, compared to 5.6% in dizygotic (DZ) 
twins, indicating a small genetic component to the disease (Feghali-Bostwick et al., 2003). 
However, there was a 90% concordance for ANA among MZ twins, compared to 40% 
among DZ (Feghali-Bostwick et al., 2003). The only twin study conducted in PBC 
demonstrated a concordance of 63% among MZ twins (Selmi et al., 2004). Although both 
twin studies note co-existing autoimmune disease, which was often the same condition in 
the twin, none have noted SSc in twins with PBC and vice versa. If one of the affected twins 
had SSc, it would be of interest to see whether the other would develop the disease, and 
within how many years after presentation of the first twin. 
2.2 Immunopathogenesis 
The immunopathogenesis of PBC has not been fully clarified, but it appears that the 
interaction between genetic predisposition, antigen-specific autoreactive T and B cells, the 
innate immune system, and environmental factors are critical in the development of the 
disease. Although PBC/SSc is relatively uncommon, several common factors found at the 
genetic and environmental levels may account for the development of the disease in this 
subgroup of patients. 
2.2.1 Genetics 
Genetic studies have recently implicated several gene loci in the pathogenesis of PBC 
(Hirschfield & Invernizzi, 2011). Strong associations between PBC and HLA DQB1, as well 
as at the IL12A, IL12RB2, STAT4 and CTLA4 loci were found in a large cohort of PBC 
patients from North America (Hirschfield & Invernizzi, 2011). The role of HLA in PBC is 
now believed to play a larger role that was previously suspected. Additionally, IRF5-
TNPO3, 17q12-21, and MMEL1 loci have also been found to be associated with PBC. A 
cohort of Japanese PBC patients also showed an association with 17q12-21, however no 
association was found with IL12A, IL12RB2 or IRF5-TNPO3, and similar findings in an 
Italian cohort have also been reported.  More recently, several new candidate genes have 
also been identified, including STAT4, DENND1B, CD80, IL7R, CXCR5, TNFRSF1A, 
CLEC16A and NFKB1. It should be noted that variability in gene associations have been 
observed between different ethnicities and/or geographical locations. 
In regards to SSc, several HLA and non-HLA regions have been identified (Agarwal & 
Reveille, 2010). Positive HLA associations in whites and Hispanics include HLA-DRB1*1104, 
DQA1*0501, DQB1*0301 (Assassi et al., 2009). Negative associations in those groups 
included DRB1*0701, DQA1*0201, DQB1*0202, and DRB1*1501 (Assassi et al., 2009). In 
African Americans, positive associations have been found with HLA-DRB1*0804, 
DQA1*0501, DQB1*0301 (Assassi et al., 2009). That study also noted that ACA positivity was 
closely associated with HLA-DQB1*0501 (Assassi et al., 2009), and another associated TOPO 
positivity with HLA-DRB1*1104. Similar HLA findings to those noted above were also 
found in a Spanish cohort. Non-HLA regions have also been identified in SSc, and include 
STAT4 (Agarwal & Reveille, 2010), IRF5 (Agarwal & Reveille, 2010), BANK1, TNSF4, TBX21, 
IL-23R , and C8orf13-BLK  among others (Agarwal & Reveille, 2010). Overlapping PBC/SSc 
genes include HLA-DRB1, DQA1, DQB1, IRF5, and STAT4, although it should be noted that 
DR11, which is positively associated with SSc, is considered protective in PBC (Agarwal & 
Reveille, 2010; Liu et al., 2010). 
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 PBC SSc 
Prevalence (highly variable 
geographically) 
28-402/million 50-200/million   
Incidence (highly variable 
geographically) 
2.3-27/million 0.6-122/million  
Male to Female Ratio 1:8 1 : 1.5-12 (highly variable 
geographically) 
Peak Frequency Age 53 years 45-64 years 
Autoantibodies AMA, ANA Limited disease: ACA, 
anti-Th/To, anti-U1-RNP 
Diffuse disease: TOPO, 
anti-RNA polymerase III, 
anti-U3-RNP 
Genes  
(positive associations) 
HLA: DRB1, DQA1, DQB1, 
DQA2 
Non-HLA: STAT4, IRF5, 
SPIB, IKZF3-ORMDL3, 
IL12A, IL12RB, MMEL1, 
DENND1B, CD80, IL7, 
CXCR5, TNFRSF1A, 
CLEC16A, NKFB1 
HLA: HLA-DRB1*1104, 
DQA1*0501, DQB1*0301, 
HLA-DRB1*0804, 
DQA1*0501, DQB1*0301 
Non-HLA: STAT4, IRF5, 
BANK1, TNSF4, TBX21, 
IL-23R, and C8orf13-BLK  
 
Table 1. Major features of primary biliary cirrhosis (PBC) and systemic sclerosis (SSc) 
2.2.2 Cellular immunity 
Autoreactive T cells are likely to be involved in the pathogenesis of PBC. Histologically, PBC 
is characterized by the presence of autoreactive T cells in the periductular spaces. CD4+ and 
CD8+ lymphocytes purified from biopsy samples of PBC patients recognize PDC-E2 
epitopes, and sequence overlap has been demonstrated between PDC-E2 specific T and B 
cell epitopes (Shimoda et al., 1995). PBC appears to be unique among other classical 
autoimmune diseases as it seems that there is only one immunodominant CD4+ epitope 
within the major autoantigen (Shimoda et al., 1995). CD4+ T cell clones have also been 
shown to recognize other mitochondrial autoantigens, including OGDC-E2, BCOADC-E2, 
and E3BP (Shimoda et al., 2003). CD8+ T cells have been found to identify amino acids 159-
167 and 165-174 of PDC-E2 (Shimoda et al., 1995). As well, a 10 fold increase in these CD8+ 
cells has been found in liver tissues compared to peripheral blood of PBC patients.  In 
regards to PBC/SSc patients, it has been reported that this patient group has clonally 
expanded CD8+ T cells expressing one T-cell receptor beta chain variable region, TCRBV3, 
which may be involved in the disease pathogenesis (Mayo et al., 1999). 
2.2.3 Humoral immunity 
AMA has been found in approximately one-quarter of patients with scleroderma, and ACA 
in one-quarter of patients with PBC. Positive ACA is reported in 9–30% of PBC patients 
(Chan et al., 1994; Marasini et al., 2001; Mayes et al., 2009; Powell et al., 1984) and in 22–25% 
of all SSc patients, the majority of which have lcSSc. AMA positivity is found in 14-25% of 
SSc (Gupta et al., 1984). ACA positivity is greater in PBC/SSc than in either disease in 
isolation, but there is no cross reactivity between mitochondrial and centromere antigens 
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(Whyte et al., 1994). Because ACA have been detected not only in SSc but also in other 
autoimmune diseases (Kallenberg et al., 1982; Miyawaki et al., 2005) including PBC (Mayes 
et al., 2009), the clinical significance of ACA has been investigated. Three major centromere 
antigens have been recognized: centromere protein A (CENP-A, 18 kD polypeptide), 
centromere protein B (CENP-B, 80 kD polypeptide), and centromere protein C (CENP-C, 140 
kD polypeptide).  One study attempted to identify the major centromeric antigen of ACA in 
sera obtained from patients with PBC, and to classify the clinical characteristics associated 
with this. Forty one patients with PBC were studied: 10 out of 16 (63%) patients with ACA 
(all anti-CENP A) had one or more lcSSc feature. The higher incidence of Raynaud’s 
phenomenon seen in ACA positive patients with PBC than in ACA negative patients with 
PBC suggested a close association of the presence of ACA with clinical features of lcSSc.  
This led to the proposal that there is a subset of PBC patients with scleroderma who are 
ACA positive, and differ from both ACA negative PBC/SSc and ACA negative PBC non-SSc 
patients, based on their clinical features and ACA epitope reactivity. As well, it has been 
suggested that there may be cross-reactivity between ACA and AMA epitopes, but no such 
link has been demonstrated (Whyte et al., 1994). 
Immunological features of PBC/SSc patients were examined in a study by Akimoto and 
colleagues (Akimoto et al., 1998), and compared to patients with PBC and SSc alone. ACA 
positivity was observed in 80% PBC/SSc, 100% PBC/SSc spectrum, 25% PBC alone, and 
100% SSc alone patients. AMA positivity was observed in 90% PBC/SSc, 75% PBC/SSc 
spectrum, 91.7% PBC alone, and 0% SSc alone patients (Akimoto et al., 1998). Interestingly, 
100% of PBC/SSc spectrum patients showed reactivity to PDC-E1β, as did 90% PBC/SSc 
patients, but only 25% of PBC alone patients (Akimoto et al., 1998). Additionally, 70.6% of 
SSc alone patients showed reactivity to PDC-E2 compared to only 23.8% of controls, and 
100% showed PDC-E3 reactivity, although this was also observed in 90.5% of controls 
(Akimoto et al., 1998). That study has suggested both clinical and immunological similarities 
in PBC/SSc and PBC/SSc spectrum patients. 
2.2.4 Infectious agents and molecular mimicry 
Infectious agents have been implicated in the pathogenesis of both SSc and PBC, and 
pathogens implicated in both are of interest in the pathogenesis of PBC/SSc. E. coli has been 
strongly associated with PBC (Bogdanos et al., 2010; Burroughs et al., 1984), largely due to 
the high occurrence of recurrent urinary tract infections in women with PBC (Corpechot et 
al., 2010; Gershwin et al., 2005). Experimental data support the presence of cross-reactive 
immune responses between human and E. coli PDC-E2 at the CD4 and CD8 T-cell level 
(Shigematsu et al., 2000; Van de Water et al., 2001). Several studies have demonstrated cross 
reactivity between the human PDC-E2 autoepitope (GDLLAEIETDKATI), and that of E. coli 
(EQSLITVEGDKASM) at the CD4 T cell level (Shimoda et al., 1995). As well, a shared motif, 
PDC-E2 (ExDK), was found to be critical for T cell epitope recognition (Shimoda et al., 1995). 
T cells specific for human PDC-E2 have also been shown to be activated by a motif sharing 
peptide of E. coli OGDC-E2 (Shimoda et al., 1995). In another study, 16 T cell clones specific 
for E. coli OGDC-E2 were tested for proliferation when stimulated by human OADC-E2 
autoepitopes from PDC-E2, OGDC-E2 and BCOADC-E2. Activation was seen in 13/16 
clones when stimulated by human OADC-E2. These studies have demonstrated that cross-
reactivity between the highly conserved human and E. coli PDC-E2 epitopes may be a factor 
in the development of PBC, but there is currently no evidence to suggest the association 
between E. coli infection and the development of SSc. 
www.intechopen.com
Emerging Issues in the Immunopathogenesis, Diagnosis  
and Clinical Management of Primary Biliary Cirrhosis Associated with Systemic Sclerosis 
 
157 
Helicobacter pylori and Chlamydia have been implicated in both PBC and SSc (Grossman et 
al., 2011; Randone et al., 2008), however some studies indicate the Chlamydia are not 
involved in the pathogenesis of these diseases (Mayes et al., 2009). DNA of H. pylori and H. 
hepaticus have been isolated from livers of patients with PBC, leading to the suggestion that 
Helicobacter species may be involved in PBC pathogenesis. Anti-helicobacter antibodies 
have been detected in the serum and the bile of PBC patients. Helicobacter species have 
induced a PBC-like pathology in experimental models of the disease. In regards to 
molecular mimicry, it has been reported that a short H. pylori urease beta subunit sequence 
shares significant amino acid similarity with the human PDC-E2212-226 autoepitope. The H. 
pylori urease beta subunit mimic has been implicated as a candidate for the initiation of 
cross-reactive immunity due to a high degree of sequence homology (13/15, 87%), and the 
fact that the mimic originates from the urease beta subunit, which is a major target antigen 
of anti-helicobacter immunity during infection. However, experimental studies have not 
demonstrated evidence of cross-reactive immunity involving H. pylori in PBC. H. pylori has 
more recently been implicated in the pathogenesis of SSc. H. pylori infection has been found 
in as many as 78% of SSc patients in one cohort, while another study notes that there is no 
difference between SSc and controls, although 90% of SSc patients had a highly virulent 
strain compared to only 37% of controls (Danese et al., 2000). 
Other pathogens implicated in SSc include herpes-virus, parvovirus B19, retroviruses, and 
human cytomegalovirus. Sequence homology has been found between retroviral proteins 
and TOPO, which is the target of anti-Scl 70 antibodies in SSc patients (Jimenez et al., 1995). 
As well, fibroblast infection with retrovirus’ has induced an SSc-like phenotype (Jimenez et 
al., 1995). It is possible that certain infectious organisms contribute the development of PBC 
or SSc in isolation, and that other organisms induce the disease in both conditions. 
Additionally, if common pathogens are implicated in both PBC and SSc, then the possibility 
of molecular mimicry in one disease may be applicable to the development of the other. 
2.3 Screening and diagnosis of PBC in SSc patients and vice versa 
Given the overlap between PBC with SSc and vice versa, including ACA positivity in PBC 
patients and AMA positivity in SSc patients, the major challenge remains to clarify which 
screening method would be best for early diagnosis of the associated conditions (Figure 1 
and 2). 
A recent study investigated the presence of antibodies against PBC disease-specific 
mitochondrial antigens and antibodies against the sp100 nuclear body antigen in 52 SSc 
patients using two commercially available ELISAs. In that study, AMA positivity was 
observed in 13%, ANA in 2%  (anti-sp100), and one patient (2%) was diagnosed with 
symptomatic PBC. These figures were also found by Mytilinaiou et al., who confirmed 
13.5% positive results with ELISA testing for antibodies against PBC disease-specific 
mitochondrial antigens in 37 SSc patients (Mytilinaiou & Bogdanos, 2009). However, this 
was not confirmed with the conventional indirect immunofluorescence based on unfixed 
rodent kidney, liver, stomach tissue sections or HEp-2 cells as antigenic substrates, and none 
of the ELISA positive patients showed features of PBC (Mytilinaiou & Bogdanos, 2009). The 
specificity of ELISA testing needs clarification in regards to whether it is less specific with 
false positive results, or that it simply represents a more sensitive method with respect to 
indirect immunofluorescence, which remains the technique of choice. 
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Systemic Sclerosis (SSc)
HISTORY AND PHYSICAL EXAMINATION
AMA
NO SYMPTOMS OR SIGNS OF 
CHOLESTATIC CHRONIC LIVER DISEASE 
AND 
NORMAL LIVER FUNCTION TESTS
POSITIVE
ABDOMINAL ULTRASOUND,
TRANSIENT ELASTOGRAPHY
SURVEILLANCE
NEGATIVE
ABNORMAL
SURVEILLANCE
NORMAL
AMA, 
ABDOMINAL ULTRASOUND,
TRANSIENT ELASTOGRAPHY
POSITIVE
REFER TO HEPATOLOGISTS
SYMPTOMS OR SIGNS OF 
CHOLESTATIC CHRONIC LIVER DISEASE 
AND / OR
ABNORMAL LIVER FUNCTION TESTS
PROBABLE PBCRECONSIDER DIAGNOSIS
NEGATIVE
 
Fig. 1. Diagnostic algorithm for patients with SSc and suspected chronic liver disease 
The presence of AMA can precede clinical symptoms of PBC. It has been demonstrated that 
the vast majority of AMA positive subjects have typical histological features of PBC despite 
being asymptomatic and having normal liver biochemistry (Metcalf et al., 1996). 
Furthermore, the study by Prince et al. suggested that 36% of initially asymptomatic PBC 
patients would become symptomatic within 5 years (Prince et al., 2004). Thus, SSc cases, and 
in particular those found to be positive for AMA, require urgent attention and long-term 
monitoring for early detection of symptoms, signs and liver biochemistry suggestive of 
chronic cholestatic liver disease. Routine follow-up of AMA positive SSc patients should 
include liver biochemical tests (alaninoaminotransferase, aspartateaminotransferase, 
gamma-glutamyltranspeptidase, alkaline phosphatase, albumin, bilirubin, international 
normalized ratio), thyroid function and possibly annual abdominal ultrasound scans. Since 
transient elastography of the liver has been emerging as a useful screening tool to detect 
undiagnosed chronic liver disease in apparently healthy subjects, this could be used to 
detect liver disease by evaluating liver stiffness on a yearly basis, and has the benefit of 
being non-invasive. In addition, transient elastography is reported to be reliable in the 
assessment biliary fibrosis. Figure 1 reports a proposed diagnostic and screening algorithm 
for PBC in SSc patients. 
Screening PBC patients for ACA is mandatory. Nakamura et al. reported that in PBC 
patients, ACA positivity was significantly associated with more severe ductular pathology 
histologically, and was a significant risk factor for the development of portal hypertension 
(Nakamura et al., 2007). In another study, ACA positive PBC patients without clinical 
features of SSc were shown to have similar symptoms and signs at diagnosis. These findings 
need to be confirmed in large multicenter studies. Although ACA positivity is not 
pathognomic of SSc, it is associated with an increased risk of developing connective tissue 
disease. One review reported a sensitivity of 32% (17–56%) for SSc, 57% (32–96%) for lcSSc, 
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and specificity of at least 93%, while ACA positivity was present in 5% of patients with 
other connective tissue diseases, and less than 1% of disease free controls. Since ACA could 
be predictive of autoimmune rheumaticological disorders, it has been suggested that an 
assessment of PBC patients should include careful questioning and evaluation for SSc 
related symptoms, such as Raynaud’s phenomenon and CREST-related symptoms 
(calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and 
teleangiectasia). The early diagnosis of SSc was recently defined into three domains 
containing seven items: skin domain (puffy fingers/puffy swollen digits turning into 
sclerodactyly), vascular domain (Raynaud's phenomenon, abnormal capillaroscopy with 
scleroderma pattern) and laboratory domain (ANA, ACA and TOPO antibodies) (Avouac et 
al., 2011). The use of nailfold video-capillaroscopy in patients suspected of having 
connective tissue disease may also be a useful indicator. It has been suggested that this 
assessment would need to be incorporated into the diagnostic and/or clinical management 
of patients with PBC and suspected SSc. Experimental and clinical observations suggest that 
endothelial dysfunction is present in PBC patients. One study found nailfold video-
capillaroscopy abnormalities in 91% of patients with PBC, and 54% had capillary alterations 
characteristic of SSc (Fonollosa et al., 2001). Eleven out of the 22 PBC patients (50%) had 
extrahepatic signs of connective tissue disease with most being related to SSc, while patients 
with other types of chronic liver disease did not present with rheumatic manifestations 
(Fonollosa et al., 2001). The high prevalence of nailfold capillary abnormalities characteristic 
of SSc in patients with PBC, and correlation with sclerodermal manifestations, suggests that 
this capillaroscopic finding could be a useful indicator to investigate rheumatic manifestations 
in these patients (Fonollosa et al., 2001). Further clinical assessment of organ involvement 
(especially lung by spirometry) in association with evaluation of pulmonary artery pressure on 
echocardiography, should be considered in PBC patients diagnosed with SSc. A proposed 
diagnostic and screening algorithm for SSc in PBC patients is presented in Figure 2. 
 
PRIMARY BILIARY CIRRHOSIS (PBC) 
HISTORY AND PHYSICAL EXAMINATION
ACA
NO SYMPTOMS OR SIGNS OF SSc
POSITIVE
NAILFOD VIDEOCAPILLAROSCOPYSURVEILLANCE
NEGATIVE
POSITIVE
ECHOCARDIOGRAPHYSURVEILLANCE
NEGATIVE
ACA, TOPO, ANA
NAILFOD VIDEOCAPILLAROSCOPY,
ECOCARDIOGRAPHY, 
SPIROMETRY
SYMPTOMS OR SIGNS OF SSc
POSITIVE
REFER TO RHEUMATOLOGIST
RECONSIDER DIAGNOSIS
NEGATIVE
DIAGNOSIS OF SSc
 
Fig. 2. Diagnostic algorithm for patients with PBC and suspected SSc 
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2.4 Clinical presentation and prognosis 
The clinical presentation of SSc precedes that of PBC in approximately 60% of cases. The 
demographics of the disease in patients with overlapping features are not well-defined. For 
example, it is not clear whether in the diagnosis of PBC in the PBC/SSc group occurs at a 
lower age than in patients with PBC alone. In a study of 43 PBC/SSc patients (Rigamonti et 
al., 2006), the median age at diagnosis of PBC made after SSc diagnosis was lower (46.1 
years) than in PBC diagnosed before SSc (51.1 years). This was lower than the diagnosis in 
PBC alone, with a median age of 53.2 years at diagnosis. The age difference at diagnosis in 
the PBC/SSc patients compared to patients with PBC alone, may be attributed to lead time 
bias (that is, screening for PBC in SSc patients and thus early diagnosis of asymptomatic 
PBC, since 56% presented with SSc alone). 
A higher first incidence of spontaneous bacterial peritonitis is found in PBC/SSc patients, in 
addition to septicaemia during follow up, when compared to patients with PBC alone. This 
is likely due to an increased risk of infection due to immune abnormalities and organ system 
manifestations associated with SSc. 
Both SSc and PBC are associated with increased morbidity and mortality (Bryan et al., 1996). 
Among the disease-related causes of death in SSc patients, pulmonary fibrosis, pulmonary 
arterial hypertension and cardiac causes (mainly heart failure and arrhythmias) are reported 
to account for the majority. The most frequent non-SSc-related causes of death are infections, 
malignancies and cardiovascular causes (Tyndall et al., 2010). In PBC patients, liver-related 
causes account for roughly 50% of deaths, whereas cardio- and cerebrovascular causes 
together with malignancies are responsible for the non-liver related deaths. Some case 
reports suggest that PBC in association with SSc is associated with a more favourable 
prognosis than PBC alone, whereas increased mortality due to SSc has been reported in 
others. In the study, which included 43 PBC/SSc patients, liver disease had a slower 
progression in PBC/SSc compared to matched patients with PBC alone (Rigamonti et al., 
2006). A lower rate of liver transplantation and liver related deaths was demonstrated in 
PBC/SSc patients compared to patients with PBC alone, and these differences were not due 
to earlier SSc related deaths. However, the improvement in liver related survival in the 
PBC/SSc cohort was outweighed by an increase in non-liver related deaths due to SSc, and 
thus overall survival was not different in PBC/SSc patients and those with PBC alone. 
Prince and colleagues observed an increase in non-hepatic deaths in asymptomatic PBC, 
even with a reduced liver related mortality, in comparison with symptomatic PBC (Prince et 
al., 2004). Since the causes of death in PBC/SSc patients are mainly due to SSc and not to 
liver disease, these patients may need different prognostic models in order to better predict 
their liver related survival. Prognostic models for PBC alone may not be applicable for PBC 
associated with SSc, or for other associated autoimmune diseases to assess the risk of liver 
related mortality and the need for liver transplantation. 
2.5 Therapy 
All PBC patients with abnormal liver biochemistry should be considered for specific 
therapy. UDCA at the dose of 13-15 mg/kg/day on a long term basis is currently considered 
the mainstay of therapy for PBC (EASL 2009). In the early stages of PBC, UDCA protects 
injured cholangiocytes against the toxic effects of bile acids. In later stages of the disease, 
UDCA stimulates impaired hepatocellular secretion, mainly by posttranscriptional 
mechanisms (Beuers, 2006). In addition, stimulation of ductular alkaline choleresis, and 
inhibition of bile acid-induced hepatocyte and cholangiocyte apoptosis are included among 
the beneficial effects of UDCA in PBC (Beuers, 2006). UDCA has been demonstrated to 
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markedly decrease serum bilirubin, alkaline phosphatase, gamma-glutamyltranspeptidase, 
cholesterol and immunoglobulin M levels, and to ameliorate histological features in patients 
with PBC in comparison to placebo treatment (Poupon et al., 1991). However, no significant 
effects on fatigue or pruritus were observed in these large trials, nor were effects on 
survival. Favorable long-term effects of UDCA are observed in patients with early disease 
and in those with a good biochemical response, which should be assessed after one year 
from start of treatment (EASL 2009). A good biochemical response after one year of UDCA 
treatment is currently defined by a serum bilirubin ≤1 mg / dl (17 micro-mol/l), alkaline 
phosphatase ≤3 x ULN and aspartate aminotransferase ≤3 x ULN, according to the ‘‘Paris 
criteria”. The “Barcelona criteria” indicate a good response with a 40% decrease or 
normalization of serum alkaline phosphatase. 
The appropriate management of SSc is complex and includes early diagnosis of internal 
organ involvement, identification of patients who are at risk of progressive disease, and 
treatments tailored for each patient. Raynaud phenomenon and ischaemic digital ulcers are 
common in patients with SSc and are a cause of disease-related morbidity. The European 
League against Rheumatism (EULAR) recommended dihydropiridine-type calcium 
antagonists, such as oral nifedipine, as first-line therapy for Raynaud phenomenon and 
intravenous prostanoid iloprost for more severe forms (Avouac et al., 2009).  The oral 
treatment with endothelin-1 receptor antagonist bosentan is the treatment of choice for SSc-
related pulmonary artery hypertension (Avouac et al., 2009).  The reportedly increased 
incidence of elevated aminotransferases with bosentan (Rubin et al., 2002) gives further 
support for the continual monitoring of liver function with this treatment, particularly in the 
special group of patients with associated PBC. Cyclophosphamide given orally should be 
considered for scleroderma interstitial lung disease (Avouac et al., 2009). Proton-pump 
inhibitors and prokinetic are used for the management of SSc-related gastrointestinal 
disease including gastroesophageal reflux, ulcers, strictures and motility disturbances. 
Scleroderma renal-crisis should be treated with Angiotensin converting-enzyme inhibitors 
(Avouac et al., 2009). 
3. Conclusions 
PBC-associated SSc is an intriguing autoimmune syndrome, which provides many 
challenges to hepatologists and rheumatologists in terms of early diagnosis and 
management, which should be shared between the two. A major effort should be made for 
continuing collaborative research in this field aimed at achieving a better understanding of 
the immunopathogenesis, genetic background, and demographic features of patients at 
higher risk of developing the associated conditions. Joint outpatient clinics between 
hepatologists and rheumatologists have been initiated in some large centers, and this may 
be a good start in the management of these complex patients. 
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